Czech National Bank Acquires 72,858 Shares of Pfizer Inc. (NYSE:PFE)

Czech National Bank boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,301,574 shares of the biopharmaceutical company's stock after buying an additional 72,858 shares during the quarter. Czech National Bank's holdings in Pfizer were worth $32,982,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter valued at $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.2%

Shares of PFE traded down $0.05 during midday trading on Monday, reaching $23.45. 30,415,590 shares of the stock were exchanged, compared to its average volume of 41,047,098. The firm has a 50 day simple moving average of $23.12 and a 200-day simple moving average of $25.05. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market cap of $133.29 billion, a price-to-earnings ratio of 16.63, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the business earned $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.34%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PFE shares. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.